Clear Creek Financial Management LLC reduced its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 11.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 5,529 shares of the company’s stock after selling 701 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Crispr Therapeutics were worth $311,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Benjamin Edwards Inc. increased its position in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc increased its position in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE increased its position in Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new position in Crispr Therapeutics in the 3rd quarter valued at approximately $26,000. Finally, BSW Wealth Partners acquired a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $465,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.
CRSP has been the subject of several recent analyst reports. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 15th. Jefferies Financial Group initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, August 1st. They set a “buy” rating and a $64.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday. Goldman Sachs Group increased their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Finally, Oppenheimer increased their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and an average price target of $69.54.
CRSP opened at $68.11 on Thursday. Crispr Therapeutics AG has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $48.67 and a 200-day moving average of $45.94. The stock has a market cap of $3.63 billion, a PE ratio of -19.80 and a beta of 3.15.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts anticipate that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is a trade deficit?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.